Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is in a challenging environment, with unpredictable and potentially costly regulatory changes and state-specific regulations. However, with operations in only one segment and revenue derived from a diverse range of services, the company is well-positioned for sustainable growth and increased profitability. Upcoming financial results are expected to show 9% revenue growth, and the company is investing in expansions and new product launches, including a new cancer test and additional indications for an existing test, which could drive further revenue and margin expansion. In addition to the usual risks associated with small-cap healthcare investments, there are specific risks involving integrating acquisitions, regulatory and reimbursement changes, new technologies, and competition. The company recently reported a modest earnings beat and raise, with particular strength in NGS and improved margins, and plans to continue focusing on these growing areas in the future.

Bears say

NeoGenomics is a company that provides oncology diagnostic testing and consultative services, and while they have recently received coverage for their PanTracer LBx test and anticipate modest revenue increase for the year, there are concerns about competition in the diagnostics industry and the potential for new technologies to disrupt their business. Despite steady performance and potential growth opportunities with new product launches and expansions into different markets, there is still a risk that this company may not be able to maintain a strong competitive edge in the long-term. Additionally, establishing materiality is a crucial factor in evaluating the company's ESG performance, and it is important to consider how factors may change over time in this evolving industry.

NeoGenomics (NEO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, NeoGenomics (NEO) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.